Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01143974
  4. Details
NCT01143974 Clinical Trial

Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer

Locally Advanced Malignant Neoplasm Clinical Trial

Official title:
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01143974
Other study ID # CH-BC-008
Secondary ID
Status Completed
Phase Phase 4
First received June 14, 2010
Last updated March 13, 2013
Start date June 2010
Est. completion date June 2012

Study information
Verified date March 2013
Source Chinese Academy of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority China: Ministry of Health
Study type Interventional

Clinical Trial Summary

For patients resistant to enthrycycline and taxanes, there is no standard regimen. Pemetrexed alone had certain efficacy in treatment of advance breast cancer. Platin was also a effective drug for advanced breast cancer. The combination of these two drug may have a synergy with each other in treatment of advanced breast cancer.

Description:

combination of pemetrexed and cisplatin to treat advanced breast cancer. Previous regimen no more than 3 which including enthrycycline and taxanes(paclitaxel and/or docetaxel)

Recruitment information / eligibility
Status Completed
Enrollment 28
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- 18-70 years old

- Resistant to enthracycle and taxanes

- Has measurable disease

Exclusion Criteria:

- Has more than 3 previous chemotherapy regimens

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• pemetrexed plus cisplatin
pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression

Locations
Country Name City State
China Cancer Institute & Hospital. Chinese Academy of Medical Sciences Beijing

Sponsors (1)
Lead Sponsor Collaborator
Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary PFS (progression free survival) 2 Years Yes
Secondary Safety Assessing for Hematology and Non-hematology toxicities, including all SAEs. 2 years Yes
Secondary Response Rate 2 years Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03671226 - Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center N/A
Completed NCT01973673 - Healthy Bones Study N/A
Completed NCT01876927 - Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer Phase 2
Terminated NCT03295942 - A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors Phase 1
Completed NCT03238027 - A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors Phase 1
Recruiting NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Phase 1/Phase 2
Completed NCT02823652 - Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer N/A
Completed NCT02227082 - Olaparib and Radiotherapy in Inoperable Breast Cancer Phase 1
Recruiting NCT01871363 - Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer Phase 2
Completed NCT01847001 - Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Phase 2
Terminated NCT03170115 - Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer Phase 2
Recruiting NCT04749108 - Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma Phase 2/Phase 3
Terminated NCT01836432 - Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Phase 3
Recruiting NCT01675999 - Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer Phase 2
Completed NCT01333709 - Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma Phase 2
Completed NCT01325558 - A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors Phase 1
Withdrawn NCT03849742 - Ride to Care - Quality of Life With Transportation for RT N/A
Active, not recruiting NCT03856060 - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits N/A
Completed NCT04186884 - Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
Recruiting NCT04112836 - Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer